Joseph Domachowske
Pediatric Infectious Diseases · Syracuse, NYNPI 1720007651
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $326,905 of the $470,276 with a category attached, or 69.5%. Sanofi Pasteur Inc. accounts for 64.2% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $142,525, 8.1 times the $17,530 reported in 2019. Among pediatric infectious diseases clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 336 payments — averaging $1399.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi Pasteur Inc.$302K
- GSK$100K
- Sanofi$22K
- Modernatx, Inc.$17K
- Shionogi Inc$8K
- Novavax Inc$7K
- plus $15K from 4 others
Across 436 payments — averaging $9473.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.3M
- Modernatx, Inc.$978K
- GSK$856K
- AstraZeneca$663K
- Astrazeneca UK Limited$195K
- Sanofi Pasteur Inc.$136K
- plus $41K from 1 others
What the payments were for
- Consulting fees$74,53816%
- Speaking & faculty fees$326,90570%
- Travel & lodging$63,04513%
- Food & beverage$5,7901%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi Pasteur Inc. | 214 | $301,801 |
| GSK | 81 | $100,303 |
| Sanofi | 6 | $22,013 |
| Modernatx, Inc. | 6 | $16,548 |
| Shionogi Inc | 3 | $7,524 |
| Novavax Inc | 9 | $7,206 |
| AstraZeneca | 13 | $7,100 |
| Merck | 2 | $5,805 |
| Abbott | 1 | $1,100 |
| Seqirus USA Inc | 1 | $875 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BEYFORTUS$156,283
- BEXSERO$97,127
- FLUZONE QUADRIVALENT$7,943
- NOVAVAX COVID-19 VACCINE, ADJUVANTED$7,086
- PENTACEL$4,922
- QUADRACEL$3,684
- ENFLONSIA$3,480
- FLUZONE HIGH-DOSE$3,361
- FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE$2,995
- DISEASE STATE$2,214
- Moderna Covid-19 Vaccine$1,620
- PENMENVY$1,500
- FLUZONE QUADRIVALENT NORTHERN HEMISPHERE$414
- NO PRODUCT DISCUSSED$115
How this compares
$470,276 in reported general payments places this provider in the 95th percentile of 73 pediatric infectious diseases providers in New York.
See all pediatric infectious diseases providers in New York →
Other pediatric infectious diseases in Syracuse
- Jana ShawWatertown$346K
- Philip LarussaNew York$125K
- Lisa SaimanNew York$73K
- Leonard KrilovMineola$64K
- Brenda TesiniRochester$45K
- Margaret HammerschlagBrooklyn$33K
- Sallie PermarNew York City$18K
- Betsy HeroldNew York$12K
- John ZahradnikGoshen$10K
- Tanya RogoBronx$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.